477872-94-9 Usage
Uses
Used in Pharmaceutical Industry:
2-(4-Methoxybenzyl)-1,3-thiazole-4-carboxylic acid is used as a building block for the synthesis of drug candidates due to its unique structural features and potential biological activity.
Used in Antimicrobial Applications:
2-(4-Methoxybenzyl)-1,3-thiazole-4-carboxylic acid is used as an antimicrobial agent, leveraging its potential to inhibit the growth of bacteria and other microorganisms, thanks to the presence of the thiazole ring in its structure.
Used in Antifungal Applications:
2-(4-Methoxybenzyl)-1,3-thiazole-4-carboxylic acid is used as an antifungal agent, indicating its potential to combat fungal infections and control the growth of fungi.
Used in Chemical Intermediates:
2-(4-Methoxybenzyl)-1,3-thiazole-4-carboxylic acid is used as a valuable chemical intermediate in the development of biologically active compounds, contributing to the creation of new pharmaceuticals and other bioactive substances.
Check Digit Verification of cas no
The CAS Registry Mumber 477872-94-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,7,8,7 and 2 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 477872-94:
(8*4)+(7*7)+(6*7)+(5*8)+(4*7)+(3*2)+(2*9)+(1*4)=219
219 % 10 = 9
So 477872-94-9 is a valid CAS Registry Number.
477872-94-9Relevant articles and documents
Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor
Jung, Hui Jin,Nam, Eun Hye,Park, Jin Young,Ghosh, Prithwish,Kim, In Su
, (2021/02/26)
Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.